- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
NeoGenomics Reports Revenue of the Fourth Quarter of 2017
NeoGenomics (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2017. As quoted in the press release: Consolidated revenues for the fourth quarter of 2017 were $67.8 million, an increase of 12% over the same period in 2016. After adjusting 2016 results for the divestiture of …
NeoGenomics (NASDAQ: NEO),a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2017.
As quoted in the press release:
Consolidated revenues for the fourth quarter of 2017 were $67.8 million, an increase of 12% over the same period in 2016. After adjusting 2016 results for the divestiture of PathLogic, revenue growth was 15%. Clinical genetic test volume(1) increased by almost 19% year over year. Average revenue per clinical genetic test (“Revenue per Test”) decreased by 8% to $338, primarily due to changes in test mix and reduced reimbursement levels for certain molecular tests.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.